Key result
Monotherapy with long-acting injectable antipsychotics reduced the risk of psychotic readmission by 15-20% compared to oral risperidone in patients with first-admission schizophrenia.
Why the study?
Antipsychotics are the main treatment for schizophrenia but their effectiveness is challenging to compare, creating a need for comparative real-world data in early-stage disease to inform clinical decisions.
Does monotherapy with long-acting injectable antipsychotics reduce readmission risk due to psychotic disorders compared to oral risperidone in first-admission schizophrenia patients?
Population
75 986 first-admission schizophrenia patients in Taiwan
Comparison
Post-discharge antipsychotics vs oral risperidone use periods
Design
Retrospective cohort study
Follow-up
Mean 8.9 years
Authors
Loading...
May support long-acting injectable use in first-admission schizophrenia; leaves open confirmation in randomized trials.
Cohort (n=75,986)
Does monotherapy with long-acting injectable antipsychotics reduce readmission risk due to psychotic disorders compared to oral risperidone in first-admission schizophrenia patients?
Lin et al. (2022) conducted a cohort in First-admission schizophrenia (n=75,986). Long-acting injectable antipsychotics (LAIs) vs. Oral risperidone was evaluated on Readmission due to psychotic disorders. Monotherapy with long-acting injectable antipsychotics reduced the risk of psychotic readmission by 15-20% compared to oral risperidone in patients with first-admission schizophrenia.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: